WEST BRIDGEWATER, Mass., Feb. 24, 2016 /PRNewswire/ — Versago Vascular Access Inc. (www.versagovascularaccess.com), developer of the world’s first “reverse needle” subcutaneous access port, has closed $1.65MM in seed funding from Primo Medical Group’s network of individual and institutional investors. Versago Vascular Access, a spinoff of Primo Medical Group and Baren-Boym Company designed and developed a new subcutaneous port to access the body’s bloodstream and anatomical cavities that collect serous or ascitic fluid. The technology provides a large bore, reusable, power injectable conduit directly into a patient’s bloodstream or other anatomical areas and in certain applications could potentially replace current technologies like ports, peripherally inserted central catheters (PICC) and central venous catheters (CVC) for a myriad of procedures. The company’s new funding will be used to further develop the Versago line of port technology, initiate regulatory review and conduct animal testing. Versago will also be initiating discussions with potential strategic partners in early 2016.